XLO · Insider Trading
Xilio Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by XLO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-02 | Yariv Houvras | CHIEF MEDICAL OFFICER | A | +105,000 deriv. | — |
| 2026-06-12 | Sara Bonstein | Director | A | +5,000 deriv. | — |
| 2026-06-12 | Daniel J. Curran | Director | A | +5,000 deriv. | — |
| 2026-06-12 | Akintunde Olatokumbo Bello | Director | A | +5,000 deriv. | — |
| 2026-06-12 | Yuan Xu | Director | A | +5,000 deriv. | — |
| 2026-06-12 | Robert W. Ross | Director | A | +5,000 deriv. | — |
| 2026-06-12 | Aoife Brennan | Director | A | +5,000 deriv. | — |
| 2026-06-12 | James Samuel Shannon | Director | A | +5,000 deriv. | — |
| 2026-04-16 | Cheryl R Blanchard | Director | A | +10,000 deriv. | — |
| 2026-03-30 | James Samuel Shannon | Director | Buy | +5,000 | +$43.95K |
| 2026-02-17 | GILEAD SCIENCES, INC. | 10%+ Owner | Buy | +3,739,000 deriv. | — |
| 2026-01-05 | Katarina Luptakova | CHIEF MEDICAL OFFICER | M | +16,625 | — |
| 2026-01-05 | Christopher James Frankenfield | Chief Financial Officer | MIXED | +12,345 | −$4.52K |
| 2026-01-05 | Rene Russo | PRESIDENT AND CEO | M | +44,250 | — |
| 2026-01-05 | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | MIXED | +3,174 | −$1.17K |
| 2025-12-01 | GILEAD SCIENCES, INC. | 10%+ Owner | X | — | — |
| 2025-11-25 | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | MIXED | +131,700 deriv. | — |
| 2025-11-25 | Katarina Luptakova | CHIEF MEDICAL OFFICER | MIXED | +625,000 deriv. | — |
| 2025-11-25 | Rene Russo | PRESIDENT AND CEO | MIXED | +2,075,000 deriv. | — |
| 2025-11-25 | Christopher James Frankenfield | Chief Financial Officer | MIXED | +614,820 deriv. | — |
| 2025-06-18 | Rene Russo | PRESIDENT AND CEO | Buy | +36,289 | +$24.68K |
| 2025-06-18 | James Samuel Shannon | Director | Buy | +70,000 | +$48.09K |
| 2025-06-18 | Rene Russo | PRESIDENT AND CEO | — | — | — |
| 2025-06-12 | Akintunde Olatokumbo Bello | Director | A | +62,000 deriv. | — |
| 2025-06-12 | Daniel J. Curran | Director | A | +31,000 deriv. | — |
| 2025-06-12 | Robert W. Ross | Director | A | +31,000 deriv. | — |
| 2025-06-12 | Paul J Clancy | Director | A | +31,000 deriv. | — |
| 2025-06-12 | Christina Rossi | Director | A | +31,000 deriv. | — |
| 2025-06-12 | Aoife Brennan | Director | A | +31,000 deriv. | — |
| 2025-06-12 | Yuan Xu | Director | A | +31,000 deriv. | — |
| 2025-06-12 | James Samuel Shannon | Director | A | +31,000 deriv. | — |
| 2025-06-12 | Sara Bonstein | Director | A | +31,000 deriv. | — |
| 2025-06-06 | GILEAD SCIENCES, INC. | 10%+ Owner | Buy | +53,340,000 deriv. | — |
| 2025-04-16 | Rene Russo | PRESIDENT AND CEO | A | +190,000 deriv. | — |
| 2025-04-16 | Christopher James Frankenfield | Chief Financial Officer | A | +75,000 deriv. | — |
| 2025-01-03 | Katarina Luptakova | CHIEF MEDICAL OFFICER | M | +16,625 | — |
| 2025-01-03 | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | MIXED | +3,197 | −$1.77K |
| 2025-01-03 | Christopher James Frankenfield | Chief Financial Officer | MIXED | +12,421 | −$6.84K |
| 2025-01-03 | Rene Russo | PRESIDENT AND CEO | M | +44,250 | — |
| 2024-12-19 | GILEAD SCIENCES, INC. | 10%+ Owner | Buy | +1,759,978 | +$1.83M |
| 2024-10-02 | Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | A | +26,000 deriv. | — |
| 2024-08-06 | Christopher James Frankenfield | Chief Operating Officer | A | +52,000 deriv. | — |
| 2024-06-17 | James Samuel Shannon | Director | A | +50,000 deriv. | — |
| 2024-06-17 | Robert W. Ross | Director | A | +25,000 deriv. | — |
| 2024-06-17 | Yuan Xu | Director | A | +25,000 deriv. | — |
| 2024-06-17 | Christina Rossi | Director | A | +25,000 deriv. | — |
| 2024-06-17 | Aoife Brennan | Director | A | +50,000 deriv. | — |
| 2024-06-17 | Paul J Clancy | Director | A | +25,000 deriv. | — |
| 2024-06-17 | Daniel J. Curran | Director | A | +25,000 deriv. | — |
| 2024-06-17 | Sara Bonstein | Director | A | +25,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| GILEAD SCIENCES, INC. | 10%+ Owner | 650,389 | $5.22M |
| Rene Russo | PRESIDENT AND CEO | 23,244 | $186.65K |
| James Samuel Shannon | Director | 10,000 | $80.30K |
| Katarina Luptakova | CHIEF MEDICAL OFFICER | 2,375 | $19.07K |
| Christopher James Frankenfield | Chief Financial Officer | 1,769 | $14.21K |
| Kevin M. Brennan | SVP, FINANCE AND ACCOUNTING | 586 | $4.71K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the XLO quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.